On April 23, 2026, the Trump administration's Department of Justice, via Acting Attorney General Todd Blanche, issued a final order rescheduling FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, providing tax relief under Section 280E and easing research barriers while leaving recreational marijuana in Schedule I. This partial reform followed the prior HHS scientific recommendation but terminated earlier proceedings, prompting a new DEA administrative hearing starting June 29, 2026, to evaluate broader rescheduling amid legal challenges and a congressional committee vote to block full changes. Traders weigh the hearing's timeline, potential delays in rulemaking, and political pressures as key factors for near-term resolution.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$758,306 Vol.
Mar 31, 2026
June 30
2%
December 31
25%
$758,306 Vol.
June 30
$336,932 Vol.
2%
December 31
$156,491 Vol.
25%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.On April 23, 2026, the Trump administration's Department of Justice, via Acting Attorney General Todd Blanche, issued a final order rescheduling FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, providing tax relief under Section 280E and easing research barriers while leaving recreational marijuana in Schedule I. This partial reform followed the prior HHS scientific recommendation but terminated earlier proceedings, prompting a new DEA administrative hearing starting June 29, 2026, to evaluate broader rescheduling amid legal challenges and a congressional committee vote to block full changes. Traders weigh the hearing's timeline, potential delays in rulemaking, and political pressures as key factors for near-term resolution.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Market Opened: Feb 7, 2026, 5:04 PM ET
Volume
$758,306End Date
Mar 31, 2026Market Opened
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.On April 23, 2026, the Trump administration's Department of Justice, via Acting Attorney General Todd Blanche, issued a final order rescheduling FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, providing tax relief under Section 280E and easing research barriers while leaving recreational marijuana in Schedule I. This partial reform followed the prior HHS scientific recommendation but terminated earlier proceedings, prompting a new DEA administrative hearing starting June 29, 2026, to evaluate broader rescheduling amid legal challenges and a congressional committee vote to block full changes. Traders weigh the hearing's timeline, potential delays in rulemaking, and political pressures as key factors for near-term resolution.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$758,306End Date
Mar 31, 2026Market Opened
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...On April 23, 2026, the Trump administration's Department of Justice, via Acting Attorney General Todd Blanche, issued a final order rescheduling FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, providing tax relief under Section 280E and easing research barriers while leaving recreational marijuana in Schedule I. This partial reform followed the prior HHS scientific recommendation but terminated earlier proceedings, prompting a new DEA administrative hearing starting June 29, 2026, to evaluate broader rescheduling amid legal challenges and a congressional committee vote to block full changes. Traders weigh the hearing's timeline, potential delays in rulemaking, and political pressures as key factors for near-term resolution.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions